Pediatric neuro-oncology: Current status and future directions

Asia-Pacific Journal of Clinical Oncology

Volumn 8, Issue 3, 2012, Pages 223-231

  Heath, John A ^a   Zacharoulis, Stergios ^b   Kieran, Mark W ^c  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

CNS cancer; Education; Pediatric oncology

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; IRINOTECAN; LOMUSTINE; PROCARBAZINE; SONIC HEDGEHOG PROTEIN; TIOGUANINE; VASCULOTROPIN; VINCRISTINE; WNT PROTEIN;

ASTROCYTOMA; BRAIN CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILDHOOD CANCER; CHROMOSOME 17; CHROMOSOME 22; CHROMOSOME 6Q; CHROMOSOME DELETION; CLINICAL TRIAL (TOPIC); ENDOCRINE DISEASE; EPENDYMOMA; HEARING LOSS; HIGH RISK PATIENT; HUMAN; MAINTENANCE CHEMOTHERAPY; MEDULLOBLASTOMA; MICROMETASTASIS; MINIMAL RESIDUAL DISEASE; NEUROFIBROMATOSIS; NEUROMONITORING; NEUROSURGERY; OVERALL SURVIVAL; PONTINE GLIOMA; PRIORITY JOURNAL; REVIEW;

CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; FORECASTING; HUMANS; MEDICAL ONCOLOGY; NEUROLOGY; PEDIATRICS;

EID: 84865402562     PISSN: 17437555     EISSN: 17437563     Source Type: Journal    
DOI: 10.1111/j.1743-7563.2012.01558.x     Document Type: Review

References (80)

1. Pollack IF. Multidisciplinary management of childhood brain tumors: a review of outcomes, recent advances, and challenges. J Neurosurg Pediatr 2011; 8: 135-48.
2. Ellison DW. Childhood medulloblastoma: novel approaches to a heterogeneous disease. Acta Neuropathol 2010; 120: 305-16.
3. Klesse LJ, Bowers DC. Childhood medulloblastoma: current status of biology and treatment. CNS Drugs 2010; 4: 285-301.
4. McManamy CS, Lamont JM, Taylor RE etal. Morphophenotypic variation predicts clinical behavior in childhood non-desmoplastic medulloblastomas. J Neuropathol Exp Neurol 2003; 62: 627-32.
5. von Hoff K, Hartmann W, von Bueren AO etal. Large cell/anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors. Pediatr Blood Cancer 2010; 54: 369-76.
6. Phi JH, Lee J, Wang KC etal. Cerebrospinal fluid M staging for medulloblastoma: reappraisal of Chang's M staging based on the CSF flow. Neuro-Oncol 2011; 13: 334-44.
7. Muoio VM, Shinio SO, Matushita H etal. Extraneural metastases in medulloblastoma. Arq Neuropsiquiatr 2011; 69: 328-31.
8. Morgenstern DA, Gibson S, Brown T etal. Clinical and pathological features of paediatric malignant rhabdoid tumours. Pediatr Blood Cancer 2010; 54: 29-34.
9. Wu X, Dagar V, Algar E etal. Rhabdoid tumour: a malignancy of early childhood with variable primary site, histology and clinical behaviour. Pathology 2008; 40: 664-70.
10. Gardner SL, Asgharzadeh S, Green A etal. Intensive induction chemotherapy with autologous hematopoietic progenitor cell rescue in young children newly diagnosed with central nervous system atypical teratoid rhabdoid tumors. Pediatr Blood Cancer 2008; 51: 235-40.
11. Finkelstein-Shechter T, Gassas A, Mabbott D etal. Atypical teratoid or rhabdoid tumors: improved outcome with high dose chemotherapy. J Pediatr Hematol Oncol 2010; 32: e182-6.
12. Kombogiorgas D, Puget S, Boddaert N etal. Appraisal of the current staging system for residual medulloblastoma by volumetric analysis. Childs Nerv Syst 2011; 27: 2101-6.
13. Packer RJ, Gajjar A, Vezina G etal. Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. J Clin Oncol 2006; 24: 4202-8.
14. Varan A. Risk-adapted chemotherapy in childhood medulloblastoma. Expert Rev Anticancer Ther 2011; 11: 771-80.
15. Merchant TE, Pollack IF, Loeffler JS. Brain tumors across the age spectrum: biology, therapy, and late effects. Semin Radiat Oncol 2010; 20: 58-66.
16. Grill J, Renaux VK, Bulteau C etal. Long-term intellectual outcome in children with posterior fossa tumors according to radiation doses and volumes. Int J Radiat Oncol Biol Phys 1999; 45: 137-45.
17. Pollack IF, Jakacki RI. Childhood brain tumors: epidemiology, current management and future directions. Nat Rev Neurol 2011; 7: 495-506.
18. Gandola L, Massimino M, Cefalo G etal. Hyperfractionated accelerated radiotherapy in the Milan strategy for metastatic medulloblastoma. J Clin Oncol. 2009; 27: 566-71.
19. Padovani L, Andre N, Gentet JC etal. Reirradiation and concomitant metronomic temozolomide: an efficient combination for local control in medulloblastoma disease? J Pediatr Hematol Oncol 2011; 33: 600-4.
20. Gajjar A, Chintagumpala M, Ashley D etal. Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. Lancet Oncol 2006; 10: 813-20.
21. Rutkowski S, von Hoff K, Emser A etal. Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. J Clin Oncol 2010; 28: 4961-8.
22. RutkowskI S, Bode U, Deinlein F etal. Treatment of early childhood medulloblastoma by postoperative chemotherapy alone. N Engl J Med 2005; 352: 978-86.
23. von Bueren AO, von Hoff K, Pietsch T etal. Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. Neuro-oncol 2011; 13: 669-79.
24. Ramaswamy V, Northcott PA, Taylor MD. FISH and chips: the recipe for improved prognostication and outcomes for children with medulloblastoma. Cancer Genet 2011; 204: 577-88.
25. Romer JT, Kimura H, Magdaleno S etal. Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1+/-p53-/- mice. Cancer Cell 2004; 6: 229-40.
26. Rudin CM, Hann CL, Laterra J etal. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009; 361: 1173-8.
27. Dakubo GD, Mazerolle CJ, Wallace VA. Expression of Notch and Wnt pathway components and activation of Notch signaling in medulloblastomas from heterozygous patched mice. J Neurooncol 2006; 79: 221-7.
28. Dahmen RP, Koch A, Denkhaus D etal. Deletions of AXIN1, a component of the WNT/wingless pathway, in sporadic medulloblastomas. Cancer Res 2001; 61: 7039-43.
29. Ryan SL, Schwalbe EC, Cole M etal. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol 2011, 123: 501-13.
30. Grotzer MA, Janss AJ, Fung K etal. TrkC expression predicts good clinical outcome in primitive neuroectodermal brain tumors. J Clin Oncol 2000; 18: 1027-35.
31. Gilbertson RJ, Pearson AD, Perry RH etal. Prognostic significance of the c-erbB-2 oncogene product in childhood medulloblastoma. Br J Cancer 1995; 71: 473-7.
32. Zacharoulis S, Moreno L. Ependymoma: an update. J Child Neurol 2009; 24: 1431-8.
33. Zacharoulis S, Ashley S, Moreno L etal. Treatment and outcome of children with relapsed ependymoma: a multi-institutional retrospective analysis. Childs Nerv Syst 2009; 26: 905-11.
34. Robertson PL, Zeltzer PM, Boyett JM etal. Survival and prognostic factors following radiation therapy and chemotherapy for ependymomas in children: a report of the Children's Cancer Group. J Neurosurg 1998; 88: 695-703.
35. Rodríguez D, Cheung MC, Housri N etal. Outcomes of malignant CNS ependymomas: an examination of 2408 cases through the Surveillance, Epidemiology, and End Results (SEER) database (1973-2005). J Surg Res 2009; 156: 340-51.
36. Venkatramani R, Dhall G, Patel M etal. Supratentorial ependymoma in children: to observe or to treat following gross total resection? Pediatr Blood Cancer 2011, 58: 380-3.
37. Goldwein JW, Corn BW, Finlay JL etal. Is craniospinal irradiation required to cure children with malignant (anaplastic) intracranial ependymomas? Cancer 1991; 67: 2766-71.
38. Zacharoulis S, Levy A, Chi SN etal. Outcome for young children newly diagnosed with ependymoma, treated with intensive induction chemotherapy followed by myeloablative chemotherapy and autologous stem cell rescue. Pediatr Blood Cancer 2007; 49: 34-40.
39. Merchant TE, Mulhern RK, Krasin MJ etal. Preliminary results from a phase II trial of conformal radiation therapy and evaluation of radiation-related CNS effects for pediatric patients with localized ependymoma. J Clin Oncol 2004; 22: 3156-62.
40. Grundy RG, Wilne SA, Weston CL etal. Primary postoperative chemotherapy without radiotherapy for intracranial ependymoma in children: the UKCCSG/SIOP prospective study. Lancet Oncol 2007; 8: 696-705.
41. Carter M, Nicholson J, Ross F etal. Genetic abnormalities detected in ependymomas by comparative genomic hybridisation. Br J Cancer 2002; 86: 929-39.
42. Gilbertson RJ, Bentley L, Hernan R etal. ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res 2002; 8: 3054-64.
43. Wright KD, Gajjar A. New chemotherapy strategies and biological agents in the treatment of childhood ependymoma. Childs Nerv Syst 2009; 25: 1275-82.
44. Korshunov A, Golanov A, Timirqaz V. Immunohistochemical markers for prognosis of epidermal neoplasms. J Neurooncol 2002; 58: 255-70.
45. Fouladi M, Stewart CF, Olson J etal. Phase 1 trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study. J Clin Oncol 2011; 29: 3529-34.
46. Kleihues P, Louis DN, Scheithauer BW etal. The WHO classification of tumors of the nervous system. J Neuropathol Exp Neurol 2002; 61: 215-25.
47. Listernick R, Charrow J, Greenwald M etal. Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study. J Pediatr 1994; 125: 63-6.
48. Thorarinsdottir HK, Santi M, McCarter R etal. Protein expression of platelet-derived growth factor receptor correlates with malignant histology and PTEN with survival in childhood gliomas. Clin Cancer Res 2008; 14: 3386-94.
49. Pollack IF, Hamilton RL, Burger PC etal. Akt activation is a common event in pediatric malignant gliomas and a potential adverse prognostic marker: a report from the Children's Oncology Group. J Neurooncol 2010; 99: 155-63.
50. Srivastava A, Jain A, Jha P etal. MGMT gene promoter methylation in pediatric glioblastomas. Childs Nerv Syst 2010; 26: 1613-18.
51. Antonelli M, Buttarelli FR, Arcella A etal. Prognostic significance of histological grading, p53 status, YKL-40 expression, and IDH1 mutations in pediatric high-grade gliomas. J Neurooncol 2010; 99: 209-15.
52. Pollack IF, Hamilton RL, James CD etal. Rarity of PTEN deletions and EGFR amplification in malignant gliomas of childhood: results from the Children's Cancer Group 945 cohort. J Neurosurg 2006; 105: 418-24.
53. Hargrave D, Bartels U, Bouffet E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 2006; 7: 241-8.
54. Wisoff JH, Sanford RA, Heier LA etal. Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children's Oncology GroupNeurosurgery 2011; 68: 1548-54.
55. Cappelli C, Grill J, Raquin M etal. Long-term follow up of 69 patients treated for optic pathway tumours before the chemotherapy era. Arch Dis Child 1998; 79: 334-8.
56. Packer RJ, Ater J, Allen J etal. Carboplatin and vincristine chemotherapy for children with newly diagnosed progressive low-grade gliomas. J Neurosurg 1997; 86: 747-54.
57. Merchant TE, Kun LE, Wu S etal. Phase II trial of conformal radiation therapy for pediatric low-grade glioma. J Clin Oncol 2009; 27: 3598-604.
58. Kieran MW, Walker D, Frappaz D etal. Brain tumors: from childhood through adolescence into adulthood. J Clin Oncol 2010; 28: 4783-9.
59. Packer RJ, Jakacki R, Horn M etal. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer 2009; 52: 791-5.
60. Pfister S, Janzarik WG, Remke M etal. BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest 2008; 118: 1739-49.
61. Jones DT, Kocialkowski S, Liu L etal. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 2009; 28: 2119-23.
62. Cohen KJ, Pollack IF, Zhou T etal. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro-oncol 2011; 13: 317-23.
63. Wisoff JH, Boyett JM, Berger MS etal. Current neurosurgical management and the impact of the extent of resection in the treatment of malignant gliomas of childhood: a report of the Children's Cancer Group trial no. CCG-945. J Neurosurg 1998; 89: 52-9.
64. Stupp R, Mason WP, Van den Bent MJ etal. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-96.
65. Cohen KJ, Heideman RL, Zhou T etal. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro-oncol 2011; 13: 410-16.
66. Oka N, Soeda A, Inagaki A etal. VEGF promotes tumorigenesis and angiogenesis of human glioblastoma stem cells. Biochem Biophys Res Commun 2007; 360: 553-9.
67. Hlobilkova A, Ehrmann J, Knizetova P etal. Analysis of VEGF, Flt-1, Flk-1, nestin and MMP-9 in relation to astocytoma pathogenesis and progression. Neoplasma 2009; 56: 284-90.
68. Verhoeff JJ, Stalpers LJ, Claes A etal. Tumour control by whole brain irradiation of anti-VEGF-treated mice bearing intracerebral glioma. Eur J Cancer 2009; 45: 3074-80.
69. Gururangan S, Chi SN, Young Poussaint T etal. Lack of efficacy of bevacizumab plus irinotecan in children with recurrent malignant glioma and diffuse brainstem glioma: a Pediatric Brain Tumor Consortium study. J Clin Oncol 2010; 28: 3069-75.
70. Faury D, Nantel A, Dunn SE etal. Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol 2007; 25: 1196-208.
71. MacDonald TJ, Aquilera D, Kramm CM. Treatment of high-grade glioma in children and adolescents. Neuro-oncol 2011; 13: 1049-58.
72. Pollack IF, Jakacki RI, Blaney SM etal. Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report. Neuro-oncol 2007; 9: 145-60.
73. Freeman BB III, Daw NC, Geyer JR etal. Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients. Cancer Invest 2006; 24: 310-17.
74. Geoerger B, Hargrave D, Thomas F etal. Innovative therapies for children with cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors. Neuro-oncol 2010; 13: 109-18.
75. De Witt Hamer PC. Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies. Neuro-oncol 2010; 12: 304-16.
76. Bode U, Buchen G, Janssen T etal. Results of a phase II trial of h-R3 monoclonal antibody (nimotuzumab) in the treatment of resistant or relapsed high-grade gliomas in children and adolescents. J Clin Oncol 2006; 24 (Suppl. 18): 1522 (abstract).
77. Massimino M, Bode U, Biassoni V etal. Nimotuzumab for pediatric diffuse intrinsic pontine gliomas. Expert Opin Biol Ther 2011; 11: 247-56.
78. Brand TM, Iida M, Li C etal. The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discov Med 2011; 12: 419-32.
79. Fan QW, Knight ZA, Goldenberg DD etal. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 2006; 9: 341-9.
80. Yan L, Bulgar A, Miao Y etal. Combined treatment with temozolomide and methoxyamine: blocking apurininc/pyrimidinic site repair coupled with targeting topoisomerase IIα. Clin Cancer Res 2007; 13: 1532-9.